Skip to content

Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery

Cytopathologic Margin Evaluation in Patients Undergoing Pancreatic Cancer Resection

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01646697
Enrollment
90
Registered
2012-07-20
Start date
2011-11-07
Completion date
2016-02-06
Last updated
2017-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma, Pancreatic Cancer

Keywords

pancreatic cancer, adenocarcinoma, pancreatic resection

Brief summary

This study is being done to investigate another way of evaluating margin status after pancreatectomy by using cytopathology (slide interpretation) as compared to the traditional method of surgical pathology

Detailed description

PRIMARY OBJECTIVES: I. To compare margin status on final pathology with margin status from cytopathologic evaluation. OUTLINE: Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.

Interventions

OTHERcytology specimen collection procedure

Undergo cytopathologic sample collection

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients undergoing pancreatic resection for a presumed, although not necessarily biopsy-proven pancreatic malignancy, * ages 18 years to 80 years old

Exclusion criteria

* Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Local recurrence at the site of resectionup to 2 yearsWill be evaluated in a Cox proportion hazards regression model. The prognostic ability of the histological reporting of the specimen margin as well as the cytopathological reporting of the specimen and in situ margins will be evaluated.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026